Quanterix 2025 Q1 Earnings Misses Targets as Net Loss Widens 83.7%
Daily EarningsTuesday, May 13, 2025 7:24 am ET
4min readQuanterix (QTRX) reported its fiscal 2025 Q1 earnings on May 12th, 2025. Revenue was slightly below expectations, reflecting ongoing financial headwinds. Guidance was adjusted in-line with market conditions, anticipating a year-over-year revenue decline. The company remains focused on strategic cost reductions and innovations to mitigate market challenges and strengthen future performance.
Revenue
Quanterix's revenue for Q1 2025 decreased by 5.4% to $30.33 million compared to the previous year. Product revenue was $20.74 million, demonstrating a slight increase. However, service and other revenue fell to $8.76 million, while collaboration and license revenue reached $771,000. Grant revenue contributed a modest $60,000, culminating in total revenues of $30.33 million.
Earnings/Net Income
Quanterix experienced a significant increase in losses, with net loss widening to $20.50 million in Q1 2025 from $11.16 million in Q1 2024. EPS losses deepened to $0.53 per share from $0.29 per share. The wider EPS indicates ongoing financial difficulties.
Price Action
The stock price of has climbed 4.18% during the latest trading day, edged down 1.38% during the most recent full trading week, and increased 2.50% month-to-date.
Post-Earnings Price Action Review
The strategy of buying shares when revenues exceed expectations and holding for 30 days has proven to be profitable, yielding a return of $1.77 per share. This approach suggests strong potential for short-term gains following positive earnings announcements. Investors who followed this strategy have seen impressive returns, highlighting the company's ability to capitalize on market reactions to favorable revenue reports. Despite recent challenges, Quanterix's financial maneuvers and strategic innovations continue to attract investor interest, indicating a resilient outlook for the company's stock performance. The effectiveness of this strategy underscores the importance of timely investment decisions based on earnings outcomes, demonstrating the potential for significant gains in the short-term market.
CEO Commentary
"During a time when market resource constraints threaten to slow scientific progress, we remain committed to keeping the innovation engine moving forward," said Masoud Toloue, CEO of Quanterix. The company announced a significant advancement by introducing Simoa ONE assay kits compatible with over 20,000 flow cytometers, reducing capital equipment needs. Despite a challenging market, Quanterix reported a solid first quarter and is taking a disciplined approach to guidance, implementing $30 million in annual cost reductions. These actions are aimed at generating positive cash flow by 2026 and streamlining integration with Akoya Biosciences.
Guidance
For 2025, Quanterix expects revenues between $120 million and $130 million, reflecting a year-over-year decline of 5% to 13%. The company anticipates GAAP gross margin of 55% to 59% and adjusted gross margin of 50% to 54%. Additionally, adjusted cash burn is projected to be approximately $35 million to $45 million.
Additional News
Quanterix recently announced an amended merger agreement with Akoya Biosciences, which will reduce the equity value of the transaction by 67% while increasing Quanterix shareholder ownership from 70% to 84% post-closing. The transaction is expected to close in June 2025. Additionally, ARUP Laboratories in the United States has begun offering a pTau217 blood test for Alzheimer’s disease utilizing the Quanterix platform and assay kit. In March, Quanterix showcased its Simoa® technology at the AD/PD conference, highlighting the benefits of a new dried blood spot extraction kit intended to expand access to high-sensitivity testing in diverse settings.
Revenue
Quanterix's revenue for Q1 2025 decreased by 5.4% to $30.33 million compared to the previous year. Product revenue was $20.74 million, demonstrating a slight increase. However, service and other revenue fell to $8.76 million, while collaboration and license revenue reached $771,000. Grant revenue contributed a modest $60,000, culminating in total revenues of $30.33 million.
Earnings/Net Income
Quanterix experienced a significant increase in losses, with net loss widening to $20.50 million in Q1 2025 from $11.16 million in Q1 2024. EPS losses deepened to $0.53 per share from $0.29 per share. The wider EPS indicates ongoing financial difficulties.
Price Action
The stock price of has climbed 4.18% during the latest trading day, edged down 1.38% during the most recent full trading week, and increased 2.50% month-to-date.
Post-Earnings Price Action Review
The strategy of buying shares when revenues exceed expectations and holding for 30 days has proven to be profitable, yielding a return of $1.77 per share. This approach suggests strong potential for short-term gains following positive earnings announcements. Investors who followed this strategy have seen impressive returns, highlighting the company's ability to capitalize on market reactions to favorable revenue reports. Despite recent challenges, Quanterix's financial maneuvers and strategic innovations continue to attract investor interest, indicating a resilient outlook for the company's stock performance. The effectiveness of this strategy underscores the importance of timely investment decisions based on earnings outcomes, demonstrating the potential for significant gains in the short-term market.
CEO Commentary
"During a time when market resource constraints threaten to slow scientific progress, we remain committed to keeping the innovation engine moving forward," said Masoud Toloue, CEO of Quanterix. The company announced a significant advancement by introducing Simoa ONE assay kits compatible with over 20,000 flow cytometers, reducing capital equipment needs. Despite a challenging market, Quanterix reported a solid first quarter and is taking a disciplined approach to guidance, implementing $30 million in annual cost reductions. These actions are aimed at generating positive cash flow by 2026 and streamlining integration with Akoya Biosciences.
Guidance
For 2025, Quanterix expects revenues between $120 million and $130 million, reflecting a year-over-year decline of 5% to 13%. The company anticipates GAAP gross margin of 55% to 59% and adjusted gross margin of 50% to 54%. Additionally, adjusted cash burn is projected to be approximately $35 million to $45 million.
Additional News
Quanterix recently announced an amended merger agreement with Akoya Biosciences, which will reduce the equity value of the transaction by 67% while increasing Quanterix shareholder ownership from 70% to 84% post-closing. The transaction is expected to close in June 2025. Additionally, ARUP Laboratories in the United States has begun offering a pTau217 blood test for Alzheimer’s disease utilizing the Quanterix platform and assay kit. In March, Quanterix showcased its Simoa® technology at the AD/PD conference, highlighting the benefits of a new dried blood spot extraction kit intended to expand access to high-sensitivity testing in diverse settings.
Disclaimer: The news articles available on this platform are generated in whole or in part by artificial intelligence and may not have been reviewed or fact checked by human editors. While we make reasonable efforts to ensure the quality and accuracy of the content, we make no representations or warranties, express or implied, as to the truthfulness, reliability, completeness, or timeliness of any information provided. It is your sole responsibility to independently verify any facts, statements, or claims prior to acting upon them. Ainvest Fintech Inc expressly disclaims all liability for any loss, damage, or harm arising from the use of or reliance on AI-generated content, including but not limited to direct, indirect, incidental, or consequential damages.
Comments
No comments yet